Standard treatment for glioblastoma (GBM) patients is surgery and radiochemotherapy (RCT) with temozolomide (TMZ). TMZ is a substrate for ABCB1, a transmembrane drug transporter. It has been suggested that survival for GBM patients receiving TMZ is influenced by different single-nucleotide variants (SNV) of ABCB1. We therefore examined SNV:s of ABCB1, namely 1199G>A, 1236C>T, 2677G>T/A, and 3435C>T and correlated to survival for GBM patients receiving RCT. In a pilot cohort (97 patients) a significant correlation to survival was found for SNV 1199G>A, with median OS for variant G/G patients being 18.2 months versus 11.5 months for A/G (p = 0.012). We found no correlation to survival for the other SNV:s. We then expanded the cohort to 179 patients (expanded cohort) and also included a confirmatory cohort (49 patients) focusing on SNV 1199G>A. Median OS for G/G versus A/G plus A/A was 15.7 and 11.5 months, respectively (p = 0.085) for the expanded cohort and 13.8 versus 16.8 months (p = 0.19) for the confirmatory. In conclusion, in patients with GBM receiving RCT with TMZ, no correlation with survival was found for the SNV:s 1236C>T, 2677G>T/A, and 3435C>T of ABCB1. Although the SNV 1199G>A might have some impact, a clinically significant role could not be confirmed.

胶质母细胞瘤（GBM）患者的标准治疗方法是使用替莫唑胺（TMZ）进行手术和放射化学疗法（RCT）。TMZ是跨膜药物转运蛋白ABCB1的底物。已经提出，接受TMZ的GBM患者的存活受到ABCB1的不同单核苷酸变体（SNV）的影响。因此，我们检查了ABCB1的SNV：1199G> A，1236C> T，2677G> T / A和3435C> T，并与接受RCT的GBM患者的生存率相关。在一个试验队列（97名患者）中，发现SNV 1199G> A与生存率显着相关，变异型G / G患者的中位OS为18.2个月，而A / G为11.5个月（p = 0.012）。我们发现与其他SNV的生存率无关。然后，我们将该队列扩大到179例患者（扩展队列），还包括一个以SNV 1199G> A为重点的确诊队列（49例患者）。G / G与A / G加A / A的OS中位数分别 为：扩展队列的15.7和11.5个月（p = 0.085），而确认组的OS的中位数OS分别为13.8和16.8个月（p  = 0.19）。总之，在GBM患者接受RCT与TMZ，与生存无相关性被发现为SNV：■1236C> T，2677G> T / A，和3435C>的Ť ABCB1。尽管SNV 1199G> A可能会产生一些影响，但无法确定其临床意义。